3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
658
Carcinoma, Non-Small-Cell Lung
455
Prostatic Neoplasms
385
Neoplasms
378
Lung Neoplasms
261
Multiple Myeloma
249
Colorectal Neoplasms
230
Neoplasm Metastasis
212
Melanoma
201
Ovarian Neoplasms
165
Leukemia, Myeloid, Acute
162
Pancreatic Neoplasms
155
Carcinoma, Renal Cell
140
Squamous Cell Carcinoma of Head and Neck
137
Lymphoma
135
Brain Neoplasms
132
Leukemia, Lymphocytic, Chronic, B-Cell
128
Glioblastoma
126
Lymphoma, Non-Hodgkin
124
Recurrence
122
Carcinoma, Hepatocellular
119
Head and Neck Neoplasms
115
Urinary Bladder Neoplasms
111
Triple Negative Breast Neoplasms
106
Stomach Neoplasms
105
Precursor Cell Lymphoblastic Leukemia-Lymphoma
103
Uterine Cervical Neoplasms
102
Hematologic Neoplasms
99
Lymphoma, Follicular
95
Sarcoma
93
Interventions
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Muscle-invasive Bladder Cancer
×
1 year
×
Clear all
NCT04660344
2026-03-27
IMvigor011
Hoffmann-La Roche
Phase 3
Active not recruiting
761 enrolled
1 FDA